Is KEYPHARM still active?

Yes, KEYPHARM is currently active.

Where is KEYPHARM registered?

KEYPHARM's registered address is Siemenslaan 11, 8020 Oostkamp, Belgium.

How many employees does KEYPHARM have?

Based on its most recently filed annual accounts (fiscal year ending 31 Dec 2025), KEYPHARM reported 18 full-time equivalent employees.

What is KEYPHARM's annual turnover?

KEYPHARM's most recently filed annual turnover (fiscal year ending 31 Dec 2025) was €14,877,926.

Did KEYPHARM make a profit or a loss?

KEYPHARM's most recently filed annual accounts (fiscal year ending 31 Dec 2025) reported a profit of €1,564,433.

When did KEYPHARM last file annual accounts?

KEYPHARM's most recently filed annual accounts cover the fiscal year ending 31 Dec 2025.

Is KEYPHARM B Corp certified?

Yes, KEYPHARM is B Corp certified. It has held the certification since 10 Jul 2023. B Lab's most recent assessment (2022) gave it an overall score of 94.3.

Does KEYPHARM hold Fairtrade certification?

No, KEYPHARM does not currently hold Fairtrade certification.

KEYPHARM

Q: When was KEYPHARM founded?

KEYPHARM was founded on 08 Sep 2006, making it 20 years old.

Q: What does KEYPHARM do?

KEYPHARM's registered main activities are Wholesale of pharmaceutical and medical goods, Business and other management consultancy activities, Manufacture of other pharmaceutical products, Holding management activities: intervention in day-to-day management, representation of companies on the basis of ownership or control of the share capital, etc., Activities of holding companies, Manufacture of basic pharmaceutical products, and Manufacture of medicaments.

BE 0883.397.311

Copied!

NV/SA

Status

Active

Founded

08 Sep 2006

Size

Small · 18 FTE

Age

20 yrs

Main activity

Wholesale of pharmaceutical and medical goods

Website

keypharm.com

About

KeyPharm develops natural, effective, safe and high-quality health and personal care products under the brand names Physalis, Biotona and Pureté bio. We are convinced that in nature lies the "Key" to a balanced and quality life. Therefore, Keypharm's mission is to improve consumer well-being with natural, - whenever possible - organic, efficient , scientifically based nutritional supplementation, aromatherapy and superfoods.

Certifications & highlights

1 certification

B Corp Certified

Certified since 10 Jul 2023

Activities

7 activities

Wholesale of pharmaceutical and medical goodsBusiness and other management consultancy activitiesManufacture of other pharmaceutical productsHolding management activities: intervention in day-to-day management, representation of companies on the basis of ownership or control of the share capital, etc.Activities of holding companiesManufacture of basic pharmaceutical productsManufacture of medicaments

Financials

Turnover2025

€14.9M+10.3%

Profit / Loss2025

€1.6M+58%

Equity2025

€5.2M+14.7%

2025	2024	2023	2022
€14,877,926+10.3%	€13,488,668+8.9%	€12,392,526+8.5%	€11,417,354
€1,564,433+58%	€990,366+23.4%	€802,767-2.7%	€825,489
€5,202,102+14.7%	€4,533,670+9.8%	€4,130,304+7.4%	€3,847,537
€4,284,021+6.8%	€4,012,626+0.4%	€3,996,936+8.8%	€3,672,451
€57,871-38.2%	€93,587-50.2%	€188,111+47.3%	€127,673
18+0.6%	17.9-1.1%	18.1+5.8%	17.1
€826,551+9.7%	€753,557+10.1%	€684,670+2.5%	€667,682

Frequently asked questions

01What is KEYPHARM's official registered name?

KEYPHARM.

02What is KEYPHARM's enterprise number (VAT number)?

BE 0883.397.311.

03What is KEYPHARM's legal form?

Naamloze vennootschap (NV) / Société anonyme (SA).

04When was KEYPHARM founded?

Sources

KBO — Kruispuntbank van Ondernemingen

NBB — Nationale Bank van België

B Corp — B Lab certification

Links

Belgian National Gazette — Publications

Check withholding obligation

Central Register of Director Disqualifications

Financial statements

	2025	2024	2023	2022
Income statement
	€14,877,926+10.3%	€13,488,668+8.9%	€12,392,526+8.5%	€11,417,354
	18+0.6%	17.9-1.1%	18.1+5.8%	17.1
	€826,551+9.7%	€753,557+10.1%	€684,670+2.5%	€667,682
	€1,354,201+2.8%	€1,317,143+14.2%	€1,153,880+2.3%	€1,127,922
	€1,964,864+48%	€1,327,910+15.9%	€1,145,931+0.4%	€1,141,148
	€2,291,779+40.9%	€1,626,375+11.2%	€1,462,843+0.2%	€1,460,639
	€1,564,433+58%	€990,366+23.4%	€802,767-2.7%	€825,489
	€38,492-19.2%	€47,633-5.2%	€50,256+46.6%	€34,287
Profitability
	15.4%+27.8%	12.1%+2.1%	11.8%-7.7%	12.8%
	10.5%+43.2%	7.3%+13.3%	6.5%-10.4%	7.2%
	30.1%+37.7%	21.8%+12.4%	19.4%-9.4%	21.5%
	16.5%+42.3%	11.6%+17.3%	9.9%-10%	11.0%
Solvency
	€9,486,123+11%	€8,546,295+5.2%	€8,127,239+8.1%	€7,519,987
	€397,348-6.2%	€423,756-14%	€492,792+61.7%	€304,697
	€13,990+49.6%	€9,352-67.5%	€28,756+213.6%	€9,169
	€5,202,102+14.7%	€4,533,670+9.8%	€4,130,304+7.4%	€3,847,537
	54.8%+3.4%	53.0%+4.4%	50.8%-0.7%	51.2%
	€451,355+13.8%	€396,569+76.7%	€224,449+36.4%	€164,564
	0.09-0.8%	0.09+61%	0.05+27.1%	0.04
	€4,284,021+6.8%	€4,012,626+0.4%	€3,996,936+8.8%	€3,672,451
	0.82-6.9%	0.89-8.5%	0.97+1.4%	0.95
	20.42+106.9%	9.87+3.3%	9.55-48.3%	18.48
Liquidity
	€57,871-38.2%	€93,587-50.2%	€188,111+47.3%	€127,673
	€6,164,461+22.4%	€5,036,855+6.5%	€4,727,445+13.2%	€4,176,575
	€1,856,9080%	€1,857,557+28.5%	€1,445,621-7.6%	€1,564,797
	€1,894,120-3%	€1,952,766+5%	€1,860,313+36.6%	€1,362,221
	€3,829,567+6.4%	€3,600,325-4.1%	€3,755,469+7.4%	€3,496,298
	2.23+6.4%	2.10+13.2%	1.85-1.9%	1.89
	€4,775,589+17.6%	€4,061,827+19.2%	€3,408,030+5%	€3,247,184
Efficiency
	46 days-9.4%	50 days+18.1%	43 days-14.9%	50 days
	56 days-13%	64 days-4.2%	67 days+11%	60 days
	244 days+6.7%	229 days-5%	241 days-11.5%	272 days
	1.650%	1.65+2.5%	1.61+30.9%	1.23
Profit appropriation
	—	—	€200,000+100%	€100,000
	€4,380,000+17.4%	€3,730,000+13.7%	€3,280,000+8.3%	€3,030,000
	€22,102+502.3%	€3,670-92.7%	€50,304+186.9%	€17,537

Sources

NBB — Nationale Bank van België

	2025	2024	2023	2022
Income statement
	€14,877,926+10.3%	€13,488,668+8.9%	€12,392,526+8.5%	€11,417,354
	18+0.6%	17.9-1.1%	18.1+5.8%	17.1
	€826,551+9.7%	€753,557+10.1%	€684,670+2.5%	€667,682
	€1,354,201+2.8%	€1,317,143+14.2%	€1,153,880+2.3%	€1,127,922
	€1,964,864+48%	€1,327,910+15.9%	€1,145,931+0.4%	€1,141,148
	€2,291,779+40.9%	€1,626,375+11.2%	€1,462,843+0.2%	€1,460,639
	€1,564,433+58%	€990,366+23.4%	€802,767-2.7%	€825,489
	€38,492-19.2%	€47,633-5.2%	€50,256+46.6%	€34,287
Profitability
	15.4%+27.8%	12.1%+2.1%	11.8%-7.7%	12.8%
	10.5%+43.2%	7.3%+13.3%	6.5%-10.4%	7.2%
	30.1%+37.7%	21.8%+12.4%	19.4%-9.4%	21.5%
	16.5%+42.3%	11.6%+17.3%	9.9%-10%	11.0%
Solvency
	€9,486,123+11%	€8,546,295+5.2%	€8,127,239+8.1%	€7,519,987
	€397,348-6.2%	€423,756-14%	€492,792+61.7%	€304,697
	€13,990+49.6%	€9,352-67.5%	€28,756+213.6%	€9,169
	€5,202,102+14.7%	€4,533,670+9.8%	€4,130,304+7.4%	€3,847,537
	54.8%+3.4%	53.0%+4.4%	50.8%-0.7%	51.2%
	€451,355+13.8%	€396,569+76.7%	€224,449+36.4%	€164,564
	0.09-0.8%	0.09+61%	0.05+27.1%	0.04
	€4,284,021+6.8%	€4,012,626+0.4%	€3,996,936+8.8%	€3,672,451
	0.82-6.9%	0.89-8.5%	0.97+1.4%	0.95
	20.42+106.9%	9.87+3.3%	9.55-48.3%	18.48
Liquidity
	€57,871-38.2%	€93,587-50.2%	€188,111+47.3%	€127,673
	€6,164,461+22.4%	€5,036,855+6.5%	€4,727,445+13.2%	€4,176,575
	€1,856,9080%	€1,857,557+28.5%	€1,445,621-7.6%	€1,564,797
	€1,894,120-3%	€1,952,766+5%	€1,860,313+36.6%	€1,362,221
	€3,829,567+6.4%	€3,600,325-4.1%	€3,755,469+7.4%	€3,496,298
	2.23+6.4%	2.10+13.2%	1.85-1.9%	1.89
	€4,775,589+17.6%	€4,061,827+19.2%	€3,408,030+5%	€3,247,184
Efficiency
	46 days-9.4%	50 days+18.1%	43 days-14.9%	50 days
	56 days-13%	64 days-4.2%	67 days+11%	60 days
	244 days+6.7%	229 days-5%	241 days-11.5%	272 days
	1.650%	1.65+2.5%	1.61+30.9%	1.23
Profit appropriation
	—	—	€200,000+100%	€100,000
	€4,380,000+17.4%	€3,730,000+13.7%	€3,280,000+8.3%	€3,030,000
	€22,102+502.3%	€3,670-92.7%	€50,304+186.9%	€17,537

2025

2024

2023

2022

Income statement

€14,877,926+10.3%

€13,488,668+8.9%

€12,392,526+8.5%

€11,417,354

18+0.6%

17.9-1.1%

18.1+5.8%

17.1

€826,551+9.7%

€753,557+10.1%

€684,670+2.5%

€667,682

€1,354,201+2.8%

€1,317,143+14.2%

€1,153,880+2.3%

€1,127,922

€1,964,864+48%

€1,327,910+15.9%

€1,145,931+0.4%

€1,141,148

€2,291,779+40.9%

€1,626,375+11.2%

€1,462,843+0.2%

€1,460,639

€1,564,433+58%

€990,366+23.4%

€802,767-2.7%

€825,489

€38,492-19.2%

€47,633-5.2%

€50,256+46.6%

€34,287

Profitability

15.4%+27.8%

12.1%+2.1%

11.8%-7.7%

12.8%

10.5%+43.2%

7.3%+13.3%

6.5%-10.4%

7.2%

30.1%+37.7%

21.8%+12.4%

19.4%-9.4%

21.5%

16.5%+42.3%

11.6%+17.3%

9.9%-10%

11.0%

Solvency

€9,486,123+11%

€8,546,295+5.2%

€8,127,239+8.1%

€7,519,987

€397,348-6.2%

€423,756-14%

€492,792+61.7%

€304,697

€13,990+49.6%

€9,352-67.5%

€28,756+213.6%

€9,169

€5,202,102+14.7%

€4,533,670+9.8%

€4,130,304+7.4%

€3,847,537

54.8%+3.4%

53.0%+4.4%

50.8%-0.7%

51.2%

€451,355+13.8%

€396,569+76.7%

€224,449+36.4%

€164,564

0.09-0.8%

0.09+61%

0.05+27.1%

0.04

€4,284,021+6.8%

€4,012,626+0.4%

€3,996,936+8.8%

€3,672,451

0.82-6.9%

0.89-8.5%

0.97+1.4%

0.95

20.42+106.9%

9.87+3.3%

9.55-48.3%

18.48

Liquidity

€57,871-38.2%

€93,587-50.2%

€188,111+47.3%

€127,673

€6,164,461+22.4%

€5,036,855+6.5%

€4,727,445+13.2%

€4,176,575

€1,856,9080%

€1,857,557+28.5%

€1,445,621-7.6%

€1,564,797

€1,894,120-3%

€1,952,766+5%

€1,860,313+36.6%

€1,362,221

€3,829,567+6.4%

€3,600,325-4.1%

€3,755,469+7.4%

€3,496,298

2.23+6.4%

2.10+13.2%

1.85-1.9%

1.89

€4,775,589+17.6%

€4,061,827+19.2%

€3,408,030+5%

€3,247,184

Efficiency

46 days-9.4%

50 days+18.1%

43 days-14.9%

50 days

56 days-13%

64 days-4.2%

67 days+11%

60 days

244 days+6.7%

229 days-5%

241 days-11.5%

272 days

1.650%

1.65+2.5%

1.61+30.9%

1.23

Profit appropriation

—

€200,000+100%

€100,000

€4,380,000+17.4%

€3,730,000+13.7%

€3,280,000+8.3%

€3,030,000

€22,102+502.3%

€3,670-92.7%

€50,304+186.9%

€17,537

KEYPHARM

About

Certifications & highlights

Activities

Financials

Frequently asked questions

All locations

Financial statements

All locations

Financial statements